pre-IPO PHARMA

COMPANY OVERVIEW

Codagenix is a clinical stage synthetic biology company that uses software to recode the genomes of viruses, constructing live-attenuated vaccines or viruses to prevent viral infections or treat solid tumors. Codagenix’s recoded vaccine candidates are a perfect antigenic match to the target virus and induce a robust immune response to all viral antigens. For cancer, our nimble platform allows us to turn a virus into a potential oncolytic immuno-oncology therapies. Both programs rely on scalable, low-cost manufacturing.


LOCATION

  • Farmingdale, NY, USA

  • THERAPEUTIC AREAS

  • Infectious Disease
  • Vaccines

  • WEBSITE

    https://codagenix.com


    CAREER WEBSITE

    None


    SOCIAL MEDIA


    INVESTORS

    topspin


    PRESS RELEASES


    Nov 2, 2022

    Codagenix Receives FDA Fast Track Designation for Live-Attenuated, Intranasal RSV Vaccine Candidate CodaVax™-RSV


    Oct 26, 2022

    Codagenix Initiates Dosing in Phase 3 Efficacy Trial of Intranasal COVID-19 Vaccine as Part of WHO-Sponsored Solidarity Trial Vaccines


    Aug 17, 2022

    Codagenix Announces Award with the US Department of Defense for Development of Balanced, Tetravalent Dengue Vaccine


    Jun 14, 2022

    Codagenix Completes Dosing in Phase 1 Trial of Universal Influenza Vaccine


    Jun 7, 2022

    Codagenix Leadership to Present at the 2022 Jefferies Healthcare Conference


    For More Press Releases


    Google Analytics Alternative